Cyclosporin a treatment for kawasaki disease refractory to initial and additional intravenous immunoglobulin

Pediatric Infectious Disease Journal

Volumn 30, Issue 10, 2011, Pages 871-876

  Suzuki, Hiroyuki ^a   Terai, Masaru ^b   Hamada, Hiromichi ^b   Honda, Takafumi ^b   Suenaga, Tomohiro ^a   Takeuchi, Takashi ^a   Yoshikawa, Norishige ^a   Shibuta, Shoichi ^c   Miyawaki, Masakazu ^c   Oishi, Ko ^d   Yamaga, Hironobu ^e   Aoyagi, Noriyuki ^f   Iwahashi, Seiji ^g   Miyashita, Ritsuko ^h   Onouchi, Yoshihiro ⁱ   Sasago, Kumiko ^j   Suzuki, Yoichi ^j   Hata, Akira ^j  

^a WAKAYAMA MEDICAL UNIVERSITY   (Japan)

^b TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^c Social Insurance Kinan Hospital   (Japan)

^d Hashimoto Municipal Hospital   (Japan)

^e Naga Municipal Hospital   (Japan)

^f WAKAYAMA ROSAI HOSPITAL   (Japan)

^g Hidaka General Hospital   (Japan)

^h Izumiotsu Municipal Hospital   (Japan)

ⁱ RIKEN   (Japan)

^j CHIBA UNIVERSITY   (Japan)

more..

Author keywords

cyclosporin A; intravenous immunoglobulin resistant (IVIG resistant); Kawasaki disease; T cell activation

Indexed keywords

ACETYLSALICYLIC ACID; C REACTIVE PROTEIN; CYCLOSPORIN A; IMMUNOGLOBULIN;

ARTICLE; CHILD; CORONARY ARTERY DISEASE; CORONARY ARTERY LESION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEART ARRHYTHMIA; HOSPITAL ADMISSION; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MUCOCUTANEOUS LYMPH NODE SYNDROME; PILOT STUDY; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; REFRACTORY MUCOCUTANEOUS LYMPH NODE SYNDROME; TREATMENT OUTCOME;

EID: 80052923016     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e318220c3cf     Document Type: Article

References (30)

1. Kawasaki T. Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of fingers and toes in children: clinical observation of 50 cases. Jpn J Allergol. 1967;16:178-222.
2. Park YW, Han JW, Park IS, et al. Kawasaki disease in Korea, 2003-2005. Pediatr Infect Dis J. 2007;26:821-823.
3. Huang WC, Huang LM, Chang IS, et al. Epidemiologic features of Kawasaki disease in Taiwan, 2003-2006. Pediatrics. 2009;123:e401-e405.
4. Holman RC, Belay ED, Christensen KY, et al. Hospitalizations for Kawasaki syndrome among children in the United States, 1997-2007. Pediatr Infect Dis J. 2010;29:483-488.
5. Harnden A, Mayon-White R, Perera R, et al. Kawasaki disease in England: ethnicity, deprivation, and respiratory pathogens. Pediatr Infect Dis J. 2009;28:21-24.
6. Nakamura Y, Yashiro M, Uehara R, et al. Epidemiologic features of Kawasaki disease in Japan: results from the nationwide survey in 2005-2006. J Epidemiol. 2008;18:167-172.
7. Newburger JW, Takahashi M, Beiser AS, et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med. 1991;324:1633-1639.
8. Takeshita S, Kawamura Y, Nakatani K, et al. Standard-dose and short-term corticosteroid therapy in immunoglobulin-resistant Kawasaki disease. Clin Pediatr (Phila). 2005;44:423-426. (Pubitemid 40868905)
9. Lang BA, Yeung ES, Oen KG, et al. Corticosteroid treatment of refractory Kawasaki disease. J Rheumatol. 2006;33:803-809.
10. Hashino K, Ishii M, Iemura M, et al. Re-treatment for immuno globulin-resistant Kawasaki disease: a comparative study of additional immune globulin and steroid pulse therapy. Pediatr Int. 2001;43:211-217. (Pubitemid 32640933)
11. Furukawa T, Kishiro M, Akimoto K, et al. Effects of steroid pulse therapy on immunoglobulin-resistant Kawasaki disease. Arch Dis Child. 2008;93: 142-146. (Pubitemid 351204755)
12. Burns JC, Mason WH, Hauger SB, et al. Infliximab treatment for refractory Kawasaki syndrome. JPediatr. 2005;146:662-667. (Pubitemid 40616253)
13. Burns JC, Best BM, Mejias A, et al. Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease. J Pediatr. 2008;153:833-836.
14. Mori M, Imagawa T, Katakura S, et al. Efficacy of plasma exchange therapy for Kawasaki disease intractable to intravenous gamma-globulin. Mod Rheumatol. 2004;14:43-47. (Pubitemid 40796159)
15. Raman V, Kim J, Sharkey A, et al. Response of refractory Kawasaki disease to pulse steroid and cyclosporine A therapy. Pediatr Infect Dis J. 2001;20: 635-637. (Pubitemid 32567732)
16. Lee TJ, Kim KH, Chun JK, et al. Low-dose methotrexate therapy for intravenous immunoglobulin-resistant Kawasaki disease. Yonsei Med J. 2008:49: 714-718.
17. Inoue Y, Okada Y, Shinohara M, et al. A multicenter prospective randomized trial of corticosteroids in primary therapy for Kawasaki disease: clinical course and coronary artery outcome. J Pediatr. 2006;149:336-341.
18. Kobayashi T, Inoue Y, Otani Y, et al. Risk stratification in the decision to include prednisolone with intravenous immunoglobulin in primary therapy of Kawasaki disease. Pediatr Infect Dis J. 2009;28:496-502.
19. Newburger JW, Sleeper LA, McCrindle BW, et al. Randomized trial of pulsed corticosteroid therapy for primary treatment of Kawasaki disease. N Engl J Med. 2007;356:663-675.
20. Okada K, Hara J, Maki I, et al. Pulse methylprednisolone with gammaglobulin as an initial treatment for acute Kawasaki disease. Eur J Pediatr. 2009;168: 181-185.
21. Onouchi Y, Gunji T, Burns JC, et al. ITPKC functional polymorphism associated with Kawasaki disease susceptibility and formation of coronary artery aneurysms. Nat Genet. 2008;40:35-42.
22. de Inocencio J, Hirsch R The role of T cells in Kawasaki disease. Crit Rev Immunol. 1995;15:349-357. (Pubitemid 26259135)
23. Brogan PA, Shah V, Clarke LA, et al. T cell activation profiles in Kawasaki syndrome. Clin Exp Immunol. 2008;151:267-274.
24. Suzuki H, Suenaga T, Takeuchi T, et al. Marker of T-cell activation is elevated in refractory Kawasaki disease. Pediatr Int. 2010;52:785-789.
25. Japanese Kawasaki disease Research Committee. Diagnostic Guidelines of Kawasaki Disease. 5th ed. Tokyo, Japan: Japanese Kawasaki disease Research Committee; 2002.
26. Igarashi T. Hyperkalemia. In: Igarashi T, ed. Clinical Pediatric Nephrology [in Japanese]. 3rd ed. Tokyo, Japan: Shindan to Chiryo Sha Inc.; 2008:39-40.
27. Ishikura K, Ikeda M, Hattori S, et al. Effective and safe treatment with cyclosporine in nephrotic children: a prospective, randomized multicenter trial. Kidney Int. 2008;73:1167-1173. (Pubitemid 351620431)
28. Hamasaki Y, Yoshikawa N, Hattori S, et al. Cyclosporine and steroid therapy in children with steroid-resistant nephritic syndrome. Pediatr Nephrol. 2009; 24:2177-2185.
29. Schwartz D, Conelly NR, Manikantan P, et al. Hyperkalemia and pyloric stenosis. Anesth Analg. 2003;97:355-357. (Pubitemid 36899728)
30. Shimizu T, Yamashiro Y, Yabuta K. Pseudohyperkalemia in Kawasaki disease. Eur J Pediatr. 1992;151:497-498.